Back
Kairos Pharma 10K Form
Sell
14
KAPA
Kairos Pharma
Last Price:
1.61
Seasonality Move:
--
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive KAPA News And Ratings
See the #1 stock for the next 7 days that we like better than KAPA
KAPA Financial Statistics
Sales & Book Value
| Annual Sales: | -- |
|---|---|
| Cash Flow: | $-168K |
| Price / Cash Flow: | 714.56 |
| Annual Sales: | $-0.07 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -0.19000 |
|---|---|
| Net Income (TTM): | $-2.01M |
| Gross Margin: | -- |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Kairos Pharma Earnings Forecast
Key Kairos Pharma Financial Ratios
- The Interest Expense is -5.41% of Operating Income.
- Per Share Earnings over the last 4 years have been positive in 0 years.
Kairos Pharma Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYAM |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | KAPA |
| Website: | kairospharma.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
KAPA Technical Analysis vs Fundamental Analysis
Sell
14
Kairos Pharma (KAPA)
is a Sell
Is Kairos Pharma a Buy or a Sell?
-
Kairos Pharma stock is rated a Sell
The current Kairos Pharma [KAPA] share price is $1.60. The Score for KAPA is 14, which is 72% below its historic median score of 50, and infers higher risk than normal.